adapalene Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 87 | 106685-40-9 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A naphthalene derivative that has specificity for RETINOIC ACID RECEPTORS. It is used as a DERMATOLOGIC AGENT for the treatment of ACNE.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 0.21 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| May 31, 1996 | FDA | GALDERMA LABS LP |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Skin burning sensation | 808.28 | 40.51 | 176 | 2786 | 10516 | 46672584 |
| Erythema | 524.76 | 40.51 | 228 | 2734 | 142592 | 46540508 |
| Dry skin | 476.82 | 40.51 | 153 | 2809 | 40863 | 46642237 |
| Acne | 467.11 | 40.51 | 128 | 2834 | 19791 | 46663309 |
| Skin exfoliation | 378.72 | 40.51 | 122 | 2840 | 32816 | 46650284 |
| Skin irritation | 344.21 | 40.51 | 82 | 2880 | 7205 | 46675895 |
| Pain of skin | 303.57 | 40.51 | 75 | 2887 | 7667 | 46675433 |
| Chemical burn of skin | 123.46 | 40.51 | 18 | 2944 | 92 | 46683008 |
| Inappropriate schedule of product administration | 121.77 | 40.51 | 66 | 2896 | 64947 | 46618153 |
| Skin swelling | 117.44 | 40.51 | 27 | 2935 | 2013 | 46681087 |
| Swelling face | 113.85 | 40.51 | 59 | 2903 | 53000 | 46630100 |
| Pruritus | 83.57 | 40.51 | 89 | 2873 | 242263 | 46440837 |
| Hypersensitivity | 56.64 | 40.51 | 58 | 2904 | 150263 | 46532837 |
| Rash | 56.29 | 40.51 | 89 | 2873 | 356423 | 46326677 |
| Dermatitis | 49.26 | 40.51 | 22 | 2940 | 14186 | 46668914 |
| Rash macular | 48.77 | 40.51 | 24 | 2938 | 19236 | 46663864 |
| Rash papular | 48.03 | 40.51 | 21 | 2941 | 12877 | 46670223 |
| Underdose | 45.47 | 40.51 | 23 | 2939 | 19535 | 46663565 |
| Skin fissures | 43.92 | 40.51 | 17 | 2945 | 7663 | 46675437 |
| Overdose | 43.25 | 40.51 | 42 | 2920 | 101937 | 46581163 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Skin burning sensation | 255.57 | 77.27 | 48 | 659 | 3732 | 29948039 |
| Erythema | 232.53 | 77.27 | 81 | 626 | 77370 | 29874401 |
| Dry skin | 170.45 | 77.27 | 48 | 659 | 22406 | 29929365 |
| Acne | 138.00 | 77.27 | 34 | 673 | 9402 | 29942369 |
| Skin exfoliation | 103.60 | 77.27 | 33 | 674 | 23139 | 29928632 |
| Skin irritation | 102.79 | 77.27 | 23 | 684 | 4169 | 29947602 |
| Pain of skin | 88.87 | 77.27 | 20 | 687 | 3713 | 29948058 |
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | D10AD03 | DERMATOLOGICALS ANTI-ACNE PREPARATIONS ANTI-ACNE PREPARATIONS FOR TOPICAL USE Retinoids for topical use in acne |
| ATC | D10AD53 | DERMATOLOGICALS ANTI-ACNE PREPARATIONS ANTI-ACNE PREPARATIONS FOR TOPICAL USE Retinoids for topical use in acne |
| FDA CS | M0018962 | Retinoids |
| FDA EPC | N0000175607 | Retinoid |
| MeSH PA | D000700 | Analgesics |
| MeSH PA | D018712 | Analgesics, Non-Narcotic |
| MeSH PA | D000893 | Anti-Inflammatory Agents |
| MeSH PA | D000894 | Anti-Inflammatory Agents, Non-Steroidal |
| MeSH PA | D018501 | Antirheumatic Agents |
| MeSH PA | D003879 | Dermatologic Agents |
| MeSH PA | D018373 | Peripheral Nervous System Agents |
| MeSH PA | D018689 | Sensory System Agents |
| CHEBI has role | CHEBI:35475 | non-steroidal anti-inflammatory drugs |
| CHEBI has role | CHEBI:50177 | dermatological agent |
| CHEBI has role | CHEBI:82665 | ndk inhibitors |
Drug Use (View source of the data)
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Acne vulgaris | indication | 88616000 | |
| Photosensitivity | contraindication | 90128006 | |
| Erythroderma | contraindication | 399992009 | |
| Inflammatory dermatosis | contraindication | 703938007 |
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 3.92 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Retinoic acid receptor gamma | Nuclear hormone receptor | AGONIST | Ki | 6.89 | CHEMBL | CHEMBL | |||
| Retinoic acid receptor beta | Nuclear hormone receptor | AGONIST | Ki | 7.47 | CHEMBL | CHEMBL | |||
| Retinoic acid receptor alpha | Nuclear hormone receptor | Ki | 5.96 | CHEMBL | |||||
| Glycine receptor subunit alpha-1 | Ion channel | EC50 | 5.89 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 1L4806J2QF | UNII |
| 4020981 | VUID |
| N0000148452 | NUI |
| D01112 | KEGG_DRUG |
| C0165631 | UMLSCUI |
| CHEBI:31174 | CHEBI |
| CHEMBL1265 | ChEMBL_ID |
| 60164 | PUBCHEM_CID |
| DB00210 | DRUGBANK_ID |
| D000068816 | MESH_DESCRIPTOR_UI |
| 6675 | INN_ID |
| 5429 | IUPHAR_LIGAND_ID |
| 153184 | RXNORM |
| 173193 | MMSL |
| 4134 | MMSL |
| 6162 | MMSL |
| 005905 | NDDF |
| 108903004 | SNOMEDCT_US |
| 386934008 | SNOMEDCT_US |
| 4020981 | VANDF |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Adapalene | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-6301 | GEL | 1 mg | TOPICAL | ANDA | 20 sections |
| Adapalene | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0168-0424 | CREAM | 1 mg | TOPICAL | ANDA | 23 sections |
| Differin | HUMAN OTC DRUG LABEL | 1 | 0299-4910 | GEL | 1 mg | TOPICAL | NDA | 14 sections |
| epiduo forte | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0299-5906 | GEL | 3 mg | TOPICAL | NDA | 25 sections |
| EPIDUO | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0299-5908 | GEL | 1 mg | TOPICAL | NDA | 24 sections |
| Differin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0299-5912 | LOTION | 0.10 g | TOPICAL | NDA | 24 sections |
| Differin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0299-5915 | CREAM | 1 mg | TOPICAL | NDA | 21 sections |
| DIFFERIN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0299-5918 | GEL | 3 mg | TOPICAL | NDA | 25 sections |
| Adapalene | HUMAN OTC DRUG LABEL | 1 | 0363-0888 | GEL | 1 mg | TOPICAL | ANDA | 14 sections |
| adapalene | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0472-0126 | GEL | 3 mg | TOPICAL | ANDA | 18 sections |
| Adapalene | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0781-7142 | GEL | 3 mg | TOPICAL | ANDA | 25 sections |
| Adapalene and Benzoyl Peroxide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0781-7182 | GEL | 1 mg | TOPICAL | ANDA | 25 sections |
| Proactiv MD Adapalene Acne Treatment | HUMAN OTC DRUG LABEL | 1 | 11410-956 | GEL | 0.10 g | TOPICAL | NDA AUTHORIZED GENERIC | 15 sections |
| Adapalene | HUMAN OTC DRUG LABEL | 1 | 11673-888 | GEL | 1 mg | TOPICAL | ANDA | 14 sections |
| Adapalene | HUMAN OTC DRUG LABEL | 1 | 21130-708 | GEL | 1 mg | TOPICAL | ANDA | 14 sections |
| Adapalene | HUMAN OTC DRUG LABEL | 1 | 36800-088 | GEL | 1 mg | TOPICAL | ANDA | 14 sections |
| Adapalene | HUMAN OTC DRUG LABEL | 1 | 41250-288 | GEL | 1 mg | TOPICAL | ANDA | 14 sections |
| Adapalene | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42546-720 | GEL | 45 g | TOPICAL | ANDA | 20 sections |
| Adapalene | HUMAN PRESCRIPTION DRUG LABEL | 1 | 45802-453 | CREAM | 0.10 g | TOPICAL | NDA | 24 sections |
| adapalene and benzoyl peroxide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 45802-846 | GEL | 0.10 g | TOPICAL | ANDA | 25 sections |
| Adapalene | HUMAN PRESCRIPTION DRUG LABEL | 1 | 49908-118 | SWAB | 1 mg | TOPICAL | ANDA | 20 sections |
| Adapalene | HUMAN OTC DRUG LABEL | 1 | 49967-354 | GEL | 1 mg | TOPICAL | ANDA | 9 sections |
| Adapalene | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-2004 | GEL | 1 mg | TOPICAL | ANDA | 19 sections |
| ADAPALENE and BENZOYL PEROXIDE | HUMAN PRESCRIPTION DRUG LABEL | 2 | 51672-1364 | GEL | 1 mg | TOPICAL | ANDA | 27 sections |
| Adapalene | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51672-1377 | GEL | 3 mg | TOPICAL | ANDA | 28 sections |
| Adapalene and Benzoyl Peroxide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 51672-1384 | GEL | 3 mg | TOPICAL | ANDA | 28 sections |
| DIFFERIN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-5030 | GEL | 1 mg | TOPICAL | NDA | 21 sections |
| Differin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-5271 | CREAM | 1 mg | TOPICAL | NDA | 12 sections |
| DIFFERIN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-5958 | GEL | 3 mg | TOPICAL | NDA | 25 sections |
| EPIDUO | HUMAN PRESCRIPTION DRUG LABEL | 2 | 54868-5991 | GEL | 1 mg | TOPICAL | NDA | 24 sections |